Dr. Kern is the CEO of LinkGevity, an AI-powered biotech company driving innovation in drug discovery for aging and resilience loss. With a distinguished background in Molecular Biology, Pharmacology, Evolutionary Biology, and Genetics, she is renowned for her pioneering work on aging mechanisms and lifespan extension. Her labs are based at the Babraham Research Campus; affiliated with the University of Cambridge.

Dr. Kern’s work has recently gained widespread excitement within the global longevity community, reflecting the growing impact of her research and its translational potential. She is a regular expert contributor on BBC News and Sky News, where she provides insight on breakthroughs in aging science and biotechnology.

Her research has led to the development of a first-in-class necrosis inhibitor targeting cellular degeneration (Anti-Necrotic™). This novel drug is advancing towards clinical trials, as a potential breakthrough treatment for aging in partnership with the UK National Health Service, with support from the UK Government, the Francis Crick Institute, and the European Union (Horizon).

The Anti-Necrotic™ drug is also backed by the UK Space Agency and NASA sponsored Space-Health program, recognizing its potential to mitigate accelerated aging in astronauts on long-duration space missions.